Small Molecules, Big Results: How JAK Inhibitors Have Transformed the Treatment of Patients with IBD
Authors:
Open Access
- 20 December 2024
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (2) , 469-477
Abstract
Small molecule Janus kinase (JAK) inhibitors have revolutionized the management of ulcerative colitis (UC) and Crohn’s disease (CD) through their low immunogenicity, safety, and consistent pharmacologic response that are superior to existing therapeutic options. In this perspective, we highlight existing evidence supporting the use of currently approved JAK inhibitors (upadacitinib, tofacitinib, and filgotinib) for UC or CD, additionally emphasizing the evidence for their use in related autoimmune conditions such as rheumatoid arthritis and spondyloarthropathies. Our perspective concludes with a review of the existing comparative effectiveness literature, which positions JAK inhibitors, particularly upadacitinib, favorably compared with other biologic therapies. This perspective is paired with a companion publication highlighting the origins and development of JAK inhibitors and a more in-depth review of their pathophysiologic mechanisms.Keywords
This publication has 60 references indexed in Scilit:
- Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn’s Disease: A Post Hoc Analysis of 3 Phase 3 TrialsClinical Gastroenterology and Hepatology, 2024
- Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing ReportsDrug Safety, 2024
- Comparative Efficacy of Advanced Therapies for Achieving Endoscopic Outcomes in Crohn’s Disease: A Systematic Review and Network Meta-AnalysisClinical Gastroenterology and Hepatology, 2024
- Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn’s DiseaseDigestive Diseases and Sciences, 2023
- Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysisInflammation Research, 2023
- Targeting IL-23 for IBD: Rationale and Progress to DateDrugs, 2023
- Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control StudyClinical Gastroenterology and Hepatology, 2021
- The regulation of JAKs in cytokine signaling and its breakdown in diseaseCytokine, 2019
- Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug TreatmentArthritis & Rheumatology, 2017
- A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2014